

対象国保健医療分野における開発ニーズ(課題)

- ・がん患者さんの増加
- ・がんの治療レベル不均衡&専門医の不足
- ・使用できる抗がん剤に限りがある
- ・抗がん剤の臨床試験が実施できていない

提案製品・技術

- ①インテリムデータウェアシステム(IDWS)
 - ・臨床試験実施のニーズを有する医療機関と現地にて臨床試験導入を検討する製薬会社を結ぶ独自のデータベース
- ②Intellim Oncology Academy (IOA)
 - ・がん治療及び抗がん剤の臨床試験を体系的に学ぶことができるトレーニングシステム(西條長宏先生監修)

本事業の内容

- ・ 契約期間:2020年3月~2020年12月
- ・ 対象国・地域:ベトナム国ハノイ市
- ・ カウンターパート機関:ベトナム国保健省、ASTT
- ・ 案件概要:IDWSに関する基礎調査(がんの診療実態、臨床試験実施状況、施設調査)及びIOAを実施するための課題の抽出及び解決策検討



開発ニーズ(課題)へのアプローチ方法(ビジネスモデル)

- ・IDWSとIOAを用いてがん治療専門医の育成と臨床試験実施基準を満たす施設を増加
- ・日本国および海外の製薬メーカーから抗がん剤の臨床試験をベトナムの病院に誘致
- ・ベトナムでの臨床試験数を2021年までにマレーシアと同水準の60試験、2023年までにタイと同水準の180試験に増加(インテリム売上192億円)

対象国に対し見込まれる成果(開発効果)

- ・がんの診断および治療の水準の向上→がん患者さんの生存期間の延長
- ・ベトナム国:医療先進国への地位向上
- ・ベトナム医療機関:臨床試験実施費用による収益増、雇用増加
- ・医療従事者:病院収益増による賃金アップ、最先端の医療知識習得

**Development Needs in the field of healthcare in Viet Nam
(Issues in the Country)**

- Increase in number of cancer patients
- Imbalanced level of cancer treatment and lack of specialists
- Limitation of anti-cancer drugs available
- Very few clinical trials conducted for anti-cancer drugs

Products/Technologies of the Company

1. Intellim Data Ware System (iDWS)
 - Our unique database which connects medical institutions with needs to conduct clinical trials and pharmaceutical companies that consider launching clinical trials in Viet Nam.
2. Intellim Oncology Academy (iOA)
 - Systematic Training System that you can learn cancer treatment and clinical trials of anti-cancer drugs (supervised by Dr. Nagahiro Saijo).

Survey Outline

- Survey Duration : March, 2020~December, 2020
- Country/Area : Socialist Republic of Viet Nam / Hanoi City
- Name of Counterpart : Ministry of Health, Viet Nam, ASTT
- Survey Overview : Basic investigation of iDWS (Status of clinical treatment for cancer and clinical trial implementation, facility investigation) and identification of issues and study of solutions for implementing IOA



Method and Approach to the Development Needs / Issues

- Using iDWS and iOA Training to increase the number of specialists for cancer treatment and the number of clinical trial sites that will satisfy basic clinical trial GCP standards
- Attracting clinical trials conducted by pharmaceutical companies in Japan and other international countries to the hospitals in Viet Nam.
- Increasing the number of oncology clinical trials up to 60 (the number in Malaysia now) by 2021 and 180 (the number in Thailand) by 2023 (sales of intellim: 19.2 billion JPY).

Expected Impact in the Country

- Improvement of the level of cancer diagnosis treatment and management for cancer → Extending survival period of cancer patients
- Viet Nam: Establishing its position as a medical advanced countries.
- Clinical sites in Viet Nam: increased profits and increased employment of skilled healthcare workers through the conducting of clinical trials
- Healthcare workers: Improved wages due to increased hospital profits, acquisition of cutting-edge medical knowledge